Chi-Shin Tseng1,2,3, Yu-Jen Wang4,5, Chung-Hsin Chen2, Shuo-Meng Wang2, Kuo-How Huang2, Po-Ming Chow2, Yeong-Shiau Pu2, Chao-Yuan Huang2, Jason Chia-Hsien Cheng1,6,7. 1. Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei 100233, Taiwan. 2. Department of Urology, National Taiwan University College of Medicine and Hospital, Taipei 100225, Taiwan. 3. Department of Medicine, National Taiwan University Hospital Jin-Shan Branch, New Taipei City 208204, Taiwan. 4. School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City 242062, Taiwan. 5. Department of Radiation Oncology and School of Medicine, Fu-Jen Catholic University Hospital and College of Medicine, New Taipei City 243089, Taiwan. 6. Division of Radiation Oncology, Department of Oncology, National Taiwan University College of Medicine and Hospital, Taipei 100229, Taiwan. 7. Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei 100233, Taiwan.
Abstract
BACKGROUND: The addition of androgen-deprivation therapy (ADT) or pelvic radiation to prostate bed salvage radiotherapy (SRT) has been debated for prostate cancer patients with biochemical recurrence (BCR) after radical prostatectomy. This study aimed to assess the outcomes and propose prediction models for exclusive prostate bed SRT. METHODS: This is a prospective observational cohort study with patients who underwent SRT with a pre-SRT PSA < 1.5 ng/mL after radical prostatectomy. Patients were treated with 70-Gy SRT to the prostate bed exclusively. Kaplan-Meier survival analyses and Cox regression analyses were applied for depicting and predicting BCR-free survival, ADT-free survival, and metastasis-free survival (MFS). Regression-based coefficients were used to develop nomograms. RESULTS: A total of 105 patients were included and 91 patients were eligible. The median follow-up period was 39 months. The 5-year BCR-free survival, ADT-free survival, and MFS were 37%, 50%, and 66%, respectively. Multivariable analysis showed that a pre-SRT PSA < 0.45 ng/mL was the only independent factor associated with longer BCR-free survival (p = 0.034), while a PSA-DT > 8 months had better ADT-free survival (p = 0.008). Patients with a PSA-DT > 8 months showed a 100% MFS and a 43% 5-year absolute benefit in MFS than a PSA-DT ≤ 8 months. All patients with a pre-SRT PSA < 0.45 ng/mL and PSA-DT > 8 months were free from subsequent ADT and any metastasis. CONCLUSIONS: In patients with a PSA < 0.45 ng/mL and PSA-DT > 8 months for post-prostatectomy BCR, prostate bed SRT provided excellent outcomes without the need for concomitant ADT or pelvic radiotherapy.
BACKGROUND: The addition of androgen-deprivation therapy (ADT) or pelvic radiation to prostate bed salvage radiotherapy (SRT) has been debated for prostate cancerpatients with biochemical recurrence (BCR) after radical prostatectomy. This study aimed to assess the outcomes and propose prediction models for exclusive prostate bed SRT. METHODS: This is a prospective observational cohort study with patients who underwent SRT with a pre-SRT PSA < 1.5 ng/mL after radical prostatectomy. Patients were treated with 70-Gy SRT to the prostate bed exclusively. Kaplan-Meier survival analyses and Cox regression analyses were applied for depicting and predicting BCR-free survival, ADT-free survival, and metastasis-free survival (MFS). Regression-based coefficients were used to develop nomograms. RESULTS: A total of 105 patients were included and 91 patients were eligible. The median follow-up period was 39 months. The 5-year BCR-free survival, ADT-free survival, and MFS were 37%, 50%, and 66%, respectively. Multivariable analysis showed that a pre-SRT PSA < 0.45 ng/mL was the only independent factor associated with longer BCR-free survival (p = 0.034), while a PSA-DT > 8 months had better ADT-free survival (p = 0.008). Patients with a PSA-DT > 8 months showed a 100% MFS and a 43% 5-year absolute benefit in MFS than a PSA-DT ≤ 8 months. All patients with a pre-SRT PSA < 0.45 ng/mL and PSA-DT > 8 months were free from subsequent ADT and any metastasis. CONCLUSIONS: In patients with a PSA < 0.45 ng/mL and PSA-DT > 8 months for post-prostatectomy BCR, prostate bed SRT provided excellent outcomes without the need for concomitant ADT or pelvic radiotherapy.
Authors: Stephen J Freedland; R Bryan Rumble; Antonio Finelli; Ronald C Chen; Susan Slovin; Mark N Stein; David S Mendelson; Colin Wackett; Howard M Sandler Journal: J Clin Oncol Date: 2014-11-03 Impact factor: 44.544
Authors: Piet Dirix; Karin Haustermans; Sara Junius; Rodney Withers; Raymond Oyen; Hendrik Van Poppel Journal: Radiother Oncol Date: 2006-04 Impact factor: 6.280
Authors: William U Shipley; Wendy Seiferheld; Himanshu R Lukka; Pierre P Major; Niall M Heney; David J Grignon; Oliver Sartor; Maltibehn P Patel; Jean-Paul Bahary; Anthony L Zietman; Thomas M Pisansky; Kenneth L Zeitzer; Colleen A F Lawton; Felix Y Feng; Richard D Lovett; Alexander G Balogh; Luis Souhami; Seth A Rosenthal; Kevin J Kerlin; James J Dignam; Stephanie L Pugh; Howard M Sandler Journal: N Engl J Med Date: 2017-02-02 Impact factor: 91.245
Authors: Mark C Markowski; Yongmei Chen; Zhaoyong Feng; Jennifer Cullen; Bruce J Trock; Daniel Suzman; Emmanuel S Antonarakis; Channing J Paller; Inger Rosner; Misop Han; Patrick C Walsh; Alan W Partin; Mario Eisenberger Journal: Clin Genitourin Cancer Date: 2019-08-21 Impact factor: 2.872
Authors: Bradley J Stish; Thomas M Pisansky; William S Harmsen; Brian J Davis; Katherine S Tzou; Richard Choo; Steven J Buskirk Journal: J Clin Oncol Date: 2016-11-10 Impact factor: 44.544
Authors: Ahmed Abugharib; William C Jackson; Vasu Tumati; Robert T Dess; Jae Y Lee; Shuang G Zhao; Moaaz Soliman; Zachary S Zumsteg; Rohit Mehra; Felix Y Feng; Todd M Morgan; Neil Desai; Daniel E Spratt Journal: J Urol Date: 2016-09-07 Impact factor: 7.450
Authors: Andrew J Stephenson; Peter T Scardino; Michael W Kattan; Thomas M Pisansky; Kevin M Slawin; Eric A Klein; Mitchell S Anscher; Jeff M Michalski; Howard M Sandler; Daniel W Lin; Jeffrey D Forman; Michael J Zelefsky; Larry L Kestin; Claus G Roehrborn; Charles N Catton; Theodore L DeWeese; Stanley L Liauw; Richard K Valicenti; Deborah A Kuban; Alan Pollack Journal: J Clin Oncol Date: 2007-05-20 Impact factor: 44.544
Authors: Thomas Van den Broeck; Roderick C N van den Bergh; Nicolas Arfi; Tobias Gross; Lisa Moris; Erik Briers; Marcus Cumberbatch; Maria De Santis; Derya Tilki; Stefano Fanti; Nicola Fossati; Silke Gillessen; Jeremy P Grummet; Ann M Henry; Michael Lardas; Matthew Liew; Olivier Rouvière; Jakub Pecanka; Malcolm D Mason; Ivo G Schoots; Theo H van Der Kwast; Henk G van Der Poel; Thomas Wiegel; Peter-Paul M Willemse; Yuhong Yuan; Thomas B Lam; Philip Cornford; Nicolas Mottet Journal: Eur Urol Date: 2018-10-17 Impact factor: 20.096
Authors: Anthony V D'Amico; Judd W Moul; Peter R Carroll; Leon Sun; Deborah Lubeck; Ming-Hui Chen Journal: J Natl Cancer Inst Date: 2003-09-17 Impact factor: 13.506
Authors: Mary Feng; Alexandra L Hanlon; Thomas M Pisansky; Deborah Kuban; Charles N Catton; Jeff M Michalski; Michael J Zelefsky; Patrick A Kupelian; Alan Pollack; Larry L Kestin; Richard K Valicenti; Theodore L DeWeese; Howard M Sandler Journal: Int J Radiat Oncol Biol Phys Date: 2007-04-06 Impact factor: 7.038
Authors: R Kanesvaran; E Castro; A Wong; K Fizazi; M L K Chua; Y Zhu; H Malhotra; Y Miura; J L Lee; F L T Chong; Y-S Pu; C-C Yen; M Saad; H J Lee; H Kitamura; K Prabhash; Q Zou; G Curigliano; E Poon; S P Choo; S Peters; E Lim; T Yoshino; G Pentheroudakis Journal: ESMO Open Date: 2022-07-04
Authors: Natalia V Bogdanova; Hoda Radmanesh; Dhanya Ramachandran; Anne Caroline Knoechelmann; Hans Christiansen; Thorsten Derlin; Christoph Alexander Joachim von Klot; Roland Merten; Christoph Henkenberens Journal: Cancers (Basel) Date: 2022-08-24 Impact factor: 6.575